Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Hosman, Anna E ^a,b,c   Devlin, Hannah L ^a,b,d,e   Silva, B Maneesha ^a,b,d   Shovlin, Claire L ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ALK1; Breast; Colorectal; Endoglin; Liver; Lung; Metastases; Prostate; SMAD4; Smoking

Indexed keywords

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CLINICAL FEATURE; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; INFORMATION PROCESSING; KIDNEY CANCER; LIFE EXPECTANCY; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH CANCER; MYELOMA; NEOPLASM; OVARY CANCER; PANCREAS CANCER; POPULATION; PRIMARY TUMOR; PROSTATE CANCER; QUESTIONNAIRE; RENDU OSLER WEBER DISEASE; SKIN CANCER; SMOKING HABIT; STOMACH CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84890491238     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-195     Document Type: Article

References (61)

1. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. Kjeldsen AD, Vase P, Green A, J Intern Med 1999 245 31 39 10.1046/j.1365-2796.1999.00398.x 10095814
2. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Dakeishi M, Shioya T, Wada Y, Shindo T, Otaka K, Manabe M, Nozaki J, Inoue S, Koizumi A, Hum Mut 2002 19 140 148 10.1002/humu.10026 11793473
3. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Plauchu H, de Chadarévian JP, Bideau A, Robert JM, Am J Med Genet 1989 32 3 291 7 10.1002/ajmg.1320320302 2729347
4. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Govani FS, Shovlin CL, Eur J Hum Genet 2009 17 860 71 10.1038/ejhg.2009.35 19337313
5. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R, J Med Genet 2011 48 73 87 10.1136/jmg.2009.069013 19553198
6. Hereditary hemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Shovlin CL, Blood Rev 2010 24 203 19 10.1016/j.blre.2010.07.001 20870325
7. Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. Finnamore H, Le Couteur J, Hickson M, Busbridge M, Whelan K, Shovlin CL, PLoS ONE 2013 8 10 76516 10.1371/journal.pone.0076516 24146883
8. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Kjeldsen A, Kjeldsen J, Am J Gastroenterol 2000 95 415 8 10.1111/j.1572-0241.2000.01792.x 10685743
9. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Krings T, Ozanne A, Chng S, Alvarez H, Rodesch G, Lasjaunias P, Neuroradiology 2005 47 711 20 10.1007/s00234-005-1390-8 16136265
10. Primary determinants of ischemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia. Shovlin CL, Jackson JE, Bamford KB, Jenkins IH, Benjamin AR, Ramadan H, Kulinskaya E, Thorax 2008 63 259 66 10.1136/thx.2007. 087452 17981912
11. Cerebral abscesses among Danish patients with hereditary haemorrhagic telangiectasia. Kjeldsen AD, Tørring PM, Nissen H, Andersen PE, Acta Neurol Scand 2013 10.1111/ane.12167. [Epub ahead of print]
12. Cerebral embolism- first manifestation of pulmonary arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Hewes RC, Auster M, White RI, Cardiovasc Intervent Radiol 1985 8 151 5 10.1007/BF02552883 4075342
13. Life threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Ference BA, Shannon TM, White RI Jr, Zawin M, Burdge CM, Chest 1994 106 1387 1392 10.1378/chest.106.5. 1387 7956388
14. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia suggested approach for obstetric services. Shovlin CL, Sodhi V, McCarthy A, Lasjaunias P, Jackson JE, Sheppard MN, BJOG 2008 115 1108 15 10.1111/j.1471-0528.2008.01786.x 18518871
15. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic telangiectasia. Buscarini E, Leandro G, Conte D, Danesino C, Daina E, Manfredi G, Lupinacci G, Brambilla G, Menozzi F, De Grazia F, Gazzaniga P, Inama G, Bonardi R, Blotta P, Forner P, Olivieri C, Perna A, Grosso M, Pongiglione G, Boccardi E, Pagella F, Rossi G, Zambelli A, Dig Dis Sci 2011 56 7 2166 78 10.1007/s10620-011-1585-2 21290179
16. European Liver Transplant Association. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. Lerut J, Orlando G, Adam R, Sabbà C, Pfitzmann R, Klempnauer J, Belghiti J, Pirenne J, Thevenot T, Hillert C, Brown CM, Gonze D, Karam V, Boillot O, Ann Surg 2006 244 854 62 10.1097/01.sla.0000247258.35406.a4 17122610
17. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jaïs X, Tregouet D, Reis A, Drouin-Garraud V, Fraisse A, Sitbon O, O'Callaghan DS, Simonneau G, Soubrier F, Humbert M, Am J Respir Crit Care Med 2010 181 851 61 10.1164/rccm.200908-1284OC 20056902
18. Elevated Factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Shovlin CL, Sulainam NL, Govani FS, Jackson JE, Begbie ME, Thromb Haemost 2007 98 1031 9 18000608
19. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary hemorrhagic telangiectasia. Livesey JA, Manning R, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, Shovlin CL, Thorax 2012 67 328 33 10.1136/thoraxjnl-2011-201076 22169361
20. Risk of colorectal cancer in juvenile polyposis. Brosens LA, van Hattem A, Hylind LM, Iacobuzio-Donahue C, Romans KE, Axilbund J, Cruz-Correa M, Tersmette AC, Offerhaus GJ, Giardiello FM, Gut 2007 56 965 7 10.1136/gut.2006.116913 17303595
21. Juvenile polyposis, hereditary hemorrhagic telangiectasia, and early onset colorectal cancer in patients with SMAD4 mutation. Schwenter F, Faughnan ME, Gradinger AB, Berk T, Gryfe R, Pollett A, Cohen Z, Gallinger S, Durno C, J Gastroenterol 2012 47 795 804 10.1007/s00535-012-0545-8 22331366
22. Antiplatelets and anticoagulants in hereditary hemorrhagic telangiectasia. Devlin HL, Hosman AE, Shovlin CL, New Engl J Med 2013 368 876 8 10.1056/NEJMc1213554
23. Life expectancy in patients with hereditary haemorrhagic telangiectasia. Sabbà C, Pasculli G, Suppressa P, D'Ovidio F, Lenato GM, Resta F, Assennato G, Guanti G, QJM 2006 99 327 34 10.1093/qjmed/hcl037 16595564
24. Life expectancy of parents with hereditary hemorrhagic telangiectasia. de Gussem EM, Edwards CP, Westermann CJJ, Faughnan ME, Mager JJ, Hematol Meet Rep 2009 3 Suppl 4 11 2
25. Survival in hereditary hemorrhagic telangiectasia. Goodwin J, Nisenbaum R, Edwards C, Faughnan ME, Hematol Meet Rep 2009 3 Suppl 4 12
26. Guttmacher AE, McKinnon WC, Taylor LA, Berg J, Porteous MEM, Korsenik J, Fayad PB, Shovlin C, Burdge CM, Jacobson B, Van Cutsem E, Westermann CJJ, Kjeldsen A, Vase P, White RI, McDonald J, Marchuk DA, The natural history of hereditary haemorrhagic telangiectasia: data from a patient questionnaire Curaçao: Conference Proceedings for HHT Foundation Int., Scientific Meeting 1997
27. GLOBOCAN, Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008 2008 http://globocan.iarc.fr
28. Cancer Research UK, CancerStats: Cancer Statistics for the UK http://www.cancerresearchuk.org/cancer-info/cancerstats/
29. Should asymptomatic patients with hereditary haemorrhagic telangiectasia (HHT) be screened for cerebral vascular malformations? Data from 22,061 years of HHT patient life. Easey AJ, Wallace GM, Hughes JM, Jackson JE, Taylor WJ, Shovlin CL, J Neurol Neurosurg Psych 2003 74 743 8 10.1136/jnnp.74.6.743
30. A questionnaire-based study suggests lifestyle and dietary factors influencing nosebleed severity in hereditary hemorrhagic telangiectasia (HHT). Silva BM, Hosman AE, Devlin HL, Shovlin CL, Laryngoscope 2013 123 1092 9 10.1002/lary.23893 23404156
31. HHT Foundation International http://www.hht.org
32. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Shovlin CL, Guttmacher AE, Buscarini E, Faughan M, Hyland R, Westermann CJJ, Plauchu H, Am J Med Genet 2000 91 66 7 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P 10751092
33. Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria? van Gent MW, Velthuis S, Post MC, Snijder RJ, Westermann CJ, Letteboer TG, Mager JJ, Am J Med Genet A 2013 161 461 6 10.1002/ajmg.a.35715
34. World Fertility Data, United Nations Population Division http://www.un.org/en/development/desa/population/theme/fertility/index.shtml
35. Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia. Govani FS, Giess A, Mollet IM, Begbie ME, Jones M, Game L, Shovlin CL, Mol Syndromol 2013 4 184 196 10.1159/000350208 23801935
36. Multiple sequence variants in hereditary hemorrhagic telangiectasia cases: illustration of complexity in molecular diagnostic interpretation. McDonald J, Gedge F, Burdette A, Carlisle J, Bukjiok C, et al. J Mol Diagnostics 2009 11 6 569 575 10.2353/jmoldx.2009.080148
37. Mutant endoglin in Hereditary Hemorrhagic Telangiectasia type I is transiently expressed intracellularly and is not a dominant negative. Pece N, Vera S, Cymerman U, White R, Wrana J, Letarte M, J Clin Invest 1997 100 2568 2579 10.1172/JCI119800 9366572
38. Expression analysis of four endoglin missense mutations suggests haploinsufficiency is the predominant mechanism for Hereditary Hemorrhagic Telangiectasia type I. Pece-Barbara N, Cymerman U, Vera S, Marchuk D, Letarte M, Hum Mol Genet 1999 8 2171 2181 10.1093/hmg/8.12.2171 10545596
39. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo GM, Dejana E, Wrana JL, Letarte M, J Biol Chem 2005 280 27800 27808 10.1074/jbc.M503471200 15923183
40. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Bourdeau A, Cymerman U, Paquet ME, Meschino W, McKinnon WC, Guttmacher AE, Becker L, Letarte M, Am J Pathol 2000 156 911 923 10.1016/S0002-9440(10)64960-7 10702408
41. Identification of Hereditary Hemorrhagic Telangiectasia type I in newborns by protein expression and mutation analysis of endoglin. Cymerman U, Vera S, Pece-Barbara N, Bourdeau A, White RI Jr, Dunn J, Letarte M, Pediatr Res 2000 47 24 35 10.1203/00006450-200001000-00008 10625079
42. Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Paquet ME, Pece-Barbara N, Vera S, Cymerman U, Karabegovic A, Shovlin C, Letarte M, Hum Mol Genet 2001 10 1347 1357 10.1093/hmg/10.13.1347 11440987
43. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Morales C, Restrepo CM, Ramirez JR, Coto E, Lenato GM, Bernabeu C, Botella LM, Hum Mutat 2006 27 295
44. Arterial endothelium-specific activin receptor- like kinase 1 expression suggests its role in arterialization and vascular remodeling. Seki T, Yun J, Oh SP, Circ Res 2003 93 682 9 10.1161/01.RES.0000095246.40391.3B 12970115
45. The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. Santibanez JF, Pérez-Gómez E, Fernandez-L A, Garrido-Martin EM, Carnero A, Malumbres M, Vary CP, Quintanilla M, Bernabéu C, Carcinogenesis 2010 31 2145 54 10.1093/carcin/bgq199 20884686
46. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN, Clin Cancer Res 2013 19 170 82 10.1158/1078-0432.CCR-12-1045 23147994
47. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H, Seon BK, Int J Cancer 2009 125 1446 53 10.1002/ijc.24482 19533687
48. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Stampino CG, Hu-Lowe D, Goumans MJ, ten Dijke P, J Biol Chem 2012 287 18551 61 10.1074/jbc.M111.338103 22493445
49. Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR, Franco M, Páez-Ribes M, Cordiner R, Fuxe J, Johansson BR, Goumans MJ, Casanovas O, ten Dijke P, Arthur HM, Pietras K, J Exp Med 2013 210 563 79 10.1084/jem.20120662 23401487
50. Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Henry LA, Johnson DA, Sarrió D, Lee S, Quinlan PR, Crook T, Thompson AM, Reis-Filho JS, Isacke CM, Oncogene 2011 30 1046 58 10.1038/onc.2010.488 21042283
51. Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis. Quintanilla M, Ramirez JR, Pérez-Gómez E, Romero D, Velasco B, Letarte M, López-Novoa JM, Bernabéu C, Oncogene 2003 22 5976 5985 10.1038/sj.onc.1206841 12955076
52. Reduced angiogenic responses in adult Endoglin heterozygous mice. Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV, Obreo J, Wang A, Pérez-Barriocanal F, Arévalo M, Bernabéu C, Letarte M, López-Novoa JM, Cardiovasc Res 2006 69 845 54 10.1016/j.cardiores.2005.11.020 16405930
53. ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R, Mol Cancer Ther 2010 9 379 388 10.1158/1535-7163.MCT-09-0650 20124460
54. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS, Clin Cancer Res 2012 18 4820 9 10.1158/1078-0432.CCR-12-0098 22767667
55. Bernabeu C, Shovlin CL, TRC-105, an anti-endoglin chimeric mAb for the potential treatment of cancer Thomson Reuters Pharma https://www.thomson-pharma. com/portal/page/portal/Reports/drug-id=17606
56. Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia. Elphick A, Shovlin CL, Laryngoscope 2013 10.1002/lary.24526
57. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Berrington De González A, Darby S, Lancet 2004 363 345 51 10.1016/S0140-6736(04)15433-0 15070562
58. Excess lifetime cancer mortality risk attributable to radiation exposure from computed tomography examinations in children. Chodick G, Ronckers C, Shalev V, Ron E, Isr Med Assoc J 2007 9 584 7 17877063
59. APSA Education Committee Review of radiation risks from computed tomography: essentials for the pediatric surgeon. Rice H, Frush D, Farmer D, Waldhausen J, J Pediatr Surg 2007 42 603 7 10.1016/j.jpedsurg.2006.12.009 17448753
60. Radiation dose to the brain and subsequent risk of developing brain tumors in pediatric patients undergoing interventional neuroradiology procedures. Thierry-Chef I, Simon SL, Land CE, Miller DL, Radiat Res 2008 170 553 65 10.1667/RR1393.1 18959462
61. Biological effects of low-dose radiation from computed tomography scanning. Ma S, Kong B, Liu B, Liu X, Int J Radiat Biol 2013 89 326 33 10.3109/09553002.2013.756595 23216318